Bloomberg Law
Nov. 17, 2022, 4:34 PMUpdated: Nov. 17, 2022, 9:40 PM

Eli Lilly’s Cheaper Insulin Can Fill in for Sanofi’s Lantus (1)

Celine Castronuovo
Celine Castronuovo

Diabetic patients will now have easier access to insulin after the FDA on Thursday approved Eli Lilly & Co.’s biosimilar as an interchangeable with the biologic drug.

Rezvoglar, which the Food and Drug Administration previously approved in December 2021, can now be swapped out as a substitute for Sanofi’s Lantus at the pharmacy counter without prior authorization from a certified medical prescriber.

Eli Lilly’s drug is the second interchangeable insulin product approved by the FDA—part of the agency’s efforts to offer and ease access to lower-cost treatments for patients.

“This approval furthers FDA’s longstanding commitment to support a competitive ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.